Clinical Trial Update: GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial tested daily GTS-21 (ispronicline) for 28 days in participants with probable Alzheimer's disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GTS-21

Snippet

Sponsor: CoMentis | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED